Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in DSGN held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | DUNHAM TRUST Co | 7.7M | $111.0M | 0.0% | 12.278% | 51.08% |
| 2 | SR ONE CAPITAL MANAGEMENT, LP | 6.5M | $94.4M | 0.0% | 10.450% | 9.09% |
| 3 | Logos Global Management LP | 3.0M | $43.4M | +53.8% | 4.803% | 1.87% |
| 4 | BAKER BROS. ADVISORS LP | 2.7M | $38.8M | +3.6% | 4.288% | 0.19% |
| 5 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.7M | $38.5M | +52.5% | 4.261% | 0.22% |
| 6 | BlackRock, Inc. | 2.7M | $38.5M | +24.7% | 4.259% | 0.00% |
| 7 | Caption Management, LLC | 2.6M | $37.9M | +2919.4% | 4.192% | 0.18% |
| 8 | Point72 Asset Management, L.P. | 2.4M | $34.2M | -13.1% | 3.789% | 0.04% |
| 9 | Trails Edge Capital Partners, LP | 2.0M | $29.0M | +134.9% | 3.204% | 4.60% |
| 10 | Frazier Life Sciences Management, L.P. | 1.8M | $26.2M | β | 2.898% | 0.57% |
| 11 | Vivo Capital, LLC | 1.6M | $23.3M | 0.0% | 2.582% | 2.13% |
| 12 | VANGUARD CAPITAL MANAGEMENT LLC | 1.6M | $22.7M | +16.4% | 2.515% | 0.00% |
| 13 | Almitas Capital LLC | 1.0M | $14.9M | -32.9% | 1.644% | 3.56% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 958K | $13.9M | +38.4% | 1.534% | 0.00% |
| 15 | Sofinnova Investments, Inc. | 865K | $12.5M | β | 1.385% | 0.65% |
| 16 | FMR LLC | 776K | $11.2M | -2.8% | 1.243% | 0.00% |
| 17 | MORGAN STANLEY | 765K | $11.1M | +16.6% | 1.226% | 0.00% |
| 18 | STATE STREET CORP | 736K | $10.7M | +11.6% | 1.179% | 0.00% |
| 19 | Woodline Partners LP | 700K | $10.1M | -27.2% | 1.121% | 0.03% |
| 20 | DIMENSIONAL FUND ADVISORS LP | 695K | $10.1M | +60.9% | 1.112% | 0.00% |
| 21 | GOLDMAN SACHS GROUP INC | 657K | $9.5M | +30.1% | 1.051% | 0.00% |
| 22 | JACOBS LEVY EQUITY MANAGEMENT, INC | 566K | $8.2M | +95.5% | 0.906% | 0.03% |
| 23 | Siren, L.L.C. | 523K | $7.6M | β | 0.838% | 0.15% |
| 24 | Qube Research & Technologies Ltd | 437K | $6.3M | +1178.6% | 0.700% | 0.01% |
| 25 | RENAISSANCE TECHNOLOGIES LLC | 388K | $5.6M | -5.0% | 0.621% | 0.01% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in DSGN β a direct measure of their conviction.
Filings activity in DSGN during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 137 | +8.7% | 84.10% | +10.84 pp | $752M | +57% |
| Q1 2026 | 126 | +6.8% | 73.26% | +9.18 pp | $479M | +35% |
| Q4 2025 | 118 | +24% | 64.08% | +3.41 pp | $354M | +39% |
| Q3 2025 | 95 | +1.1% | 60.67% | 0.11 pp | $255M | +124% |
| Q2 2025 | 94 | 4.1% | 60.78% | +1.64 pp | $114M | 9.9% |
| Q1 2025 | 98 | +4.3% | 59.14% | +1.82 pp | $126M | 35% |
| Q4 2024 | 94 | 6.0% | 57.32% | +1.65 pp | $195M | +19% |
| Q3 2024 | 100 | β | 55.67% | β | $164M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Rare Disease Biotech peers.
| Ticker | Company | Market Cap | Inst. Ownership | Holders | Net Buyers β Sellers |
|---|---|---|---|---|---|
| IRLA | IRulya Therapeutics Inc. | $39M | 23.9% | 42 | -29 |
Quick answers to the most common questions about buying DSGN stock.
Based on Q2 2026 13F filings, institutional ownership of Design Therapeutics, Inc. stands at 84.1%, held across 137 reporting institutions.
DUNHAM TRUST Co is the largest reported institutional holder of DSGN, with approximately 7,668,710 shares worth $0.11B as of Q2 2026.
Yes β 2 widely-followed marquee investors appear among the top 25 institutional holders of DSGN, including Point72 Asset Management, L.P., RENAISSANCE TECHNOLOGIES LLC.
Our composite Smart Money Score for DSGN is 69 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
27 institutions opened new positions in DSGN during Q2 2026, while 16 fully exited. 87 added to existing positions and 21 trimmed.
DSGN institutional ownership rose by 10.84 percentage points quarter-over-quarter, with a net change of +11 holders.
The top 10 institutions account for 65.4% of all reported 13F value in DSGN, and the top 25 account for 89.1%.
Across the largest Rare Disease Biotech peers, institutional ownership levels are: IRLA (23.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.